To include your compound in the COVID-19 Resource Center, submit it here.

Shionogi's lusutrombopag meets in Phase III for thrombocytopenia

In September, Shionogi & Co. Ltd. (Tokyo:4507) reported top-line data from the Phase III L-PLUS2 trial in 215 chronic liver disease patients with thrombocytopenia undergoing non-emergent invasive procedures showing that once-daily oral 3 mg lusutrombopag (S-888711) met

Read the full 370 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE